Skip to main content

Advertisement

SpringerLink
Log in

Periprocedural Anticoagulation and Antiplatelet Medications Management for Interventional Radiology Procedures

  • QUALITY AND SAFETY (H ABUJUDEH, SECTION EDITOR)
  • Published:
Current Radiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

A large subset of patients undergoing Interventional Radiology procedures are on anticoagulation and/or antiplatelet therapy. Therefore, careful assessment of the coagulation status should be part of every patient's preprocedural evaluation to minimize the risk of bleeding. Every Interventional radiologist should be aware of the different medications that can affect coagulation parameters and how to properly manage them.

Recent Findings

After a thorough literature search, the most recent and relevant articles on periprocedural management of anticoagulation and antiplatelet medications for patients undergoing percutaneous and endovascular image-guided procedures were reviewed. Consensus guidelines from the Society of Interventional Radiology and other society guidelines showed few differences; however, there is no strong evidence on the definite timing to stop and resume those medications safely in the periprocedural period.

Summary

Currently used anticoagulation and antiplatelet medications are discussed in this review, with regards to their mechanism of action, pharmacokinetics, indications, and periprocedural management according to recent studies and different societal guidelines. The recommendations are presented in a clear and easy to follow diagram and table, along with recommendations regarding drug reversal. In addition, a brief review of the basic principles, physiology, and pharmacology of hemostasis is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently have been highlighted as: • Of importance and •• Of major importance

  1. Taslakian B, Sebaaly MG, Al-Kutoubi A. Patient evaluation and preparation in vascular and interventional radiology: what every interventional radiologist should know (part 2: patient preparation and medications). Cardiovasc Intervent Radiol. 2016;39(4):489–99. https://doi.org/10.1007/s00270-015-1239-4.

    Article  PubMed  Google Scholar 

  2. Malloy PC, Grassi CJ, Kundu S, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2009. https://doi.org/10.1016/j.jvir.2008.11.027.

    Article  PubMed  Google Scholar 

  3. Patel IJ, Davidson JC, Nikolic B, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727–36. https://doi.org/10.1016/j.jvir.2012.02.012.

    Article  PubMed  Google Scholar 

  4. Patel IJ, Davidson JC, Nikolic B, et al. Addendum of newer anticoagulants to the SIR consensus guideline. J Vasc Interv Radiol. 2013;24(5):641–5. https://doi.org/10.1016/j.jvir.2012.12.007.

    Article  PubMed  Google Scholar 

  5. •• Davidson JC, Rahim S, Hanks SE, et al. Society of Interventional Radiology Consensus Guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions—part I: review of anticoagulation agents and clinical considerations. J Vasc Interv Radiol. 2019;30(8):1155–67. https://doi.org/10.1016/j.jvir.2019.04.016. This reference is part 1 of the most recent Society of Interventional Radiology guidelines for peri-procedural management of anticoagulation and antiplatelet medications. It discusses the physiology or hemostasis and pharmacology of the most commonly used anticoagulation and antiplatelet medications.

  6. •• Patel IJ, Rahim S, Davidson JC, et al. Society of Interventional Radiology Consensus Guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions—Part II: recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019. https://doi.org/10.1016/j.jvir.2019.04.017. This reference is part 2 of the most recent Society of Interventional Radiology guidelines for peri-procedural management of anticoagulation and antiplatelet medications. It discusses the recommendations on how to manage those medications before and after image guided procedures.

  7. Gale AJ. Continuing education course #2: current understanding of hemostasis. Toxicol Pathol. 2011;39(1):273–80. https://doi.org/10.1177/0192623310389474.

    Article  PubMed  Google Scholar 

  8. Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013;93:327–58. https://doi.org/10.1152/physrev.00016.2011.

    Article  CAS  PubMed  Google Scholar 

  9. Beshay JE, Morgan H, Madden C, Yu W, Sarode R. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. J Neurosurg. 2010;112(2):307–18. https://doi.org/10.3171/2009.7.JNS0982.

    Article  CAS  PubMed  Google Scholar 

  10. Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(4):709–25. https://doi.org/10.1161/ATVBAHA.117.309846.

    Article  CAS  PubMed  Google Scholar 

  11. • Atwell TD, Wennberg PW, McMenomy BP, et al. Peri-procedural use of anticoagulants in radiology: an evidence-based review. Abdom Radiol. 2017;42:1556–65. A review article that discusses the periprocedural management of anticoagulants and antiplatelets for percutaneous image guided procedures, with suggested guidelines regarding when to stop and resume the medications. The paper is published out of Mayo Clinic, and shows slight variability in management recommendation from societal consensus guidelines.

  12. Lijfering WM, Tichelaar YIGV. Direct oral anticoagulant use and risk of perioperative bleeding: evidence of absence or absence of evidence? Res Pract Thromb Haemost. 2018;2(2):182–5. https://doi.org/10.1002/rth2.12084.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368(22):2113–24. https://doi.org/10.1056/NEJMra1206531.

    Article  CAS  PubMed  Google Scholar 

  14. •Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:199S-233S. https://doi.org/10.1378/chest.08-0672. This reference is the clinical practic guidelines by the American College of Chest Physicians and it reviews the different antiplatelet medications, with emphasis their pharmacology, indications and adverse effects.

  15. Coleman JL, Alberts MJ. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. Am J Cardiol. 2006;98(6):838–41. https://doi.org/10.1016/j.amjcard.2006.03.071.

    Article  CAS  PubMed  Google Scholar 

  16. Cahill RA, McGreal GT, Crowe BH, et al. Duration of increased bleeding tendency after cessation of aspirin therapy. J Am Coll Surg. 2005;200(4):564–73. https://doi.org/10.1016/j.jamcollsurg.2004.11.002.

    Article  PubMed  Google Scholar 

  17. •• Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy. Antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e326S-e350S. https://doi.org/10.1378/chest.11-2298. This reference is the management guidelines for antithrombotic medications in the perioperative period, by the American College of Chest Physicians.

  18. Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-close aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005;257(5):399–414. https://doi.org/10.1111/j.1365-2796.2005.01477.x.

    Article  CAS  PubMed  Google Scholar 

  19. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 1999;106(5B):25S-36S. https://doi.org/10.1016/S0002-9343(99)00114-X.

    Article  CAS  PubMed  Google Scholar 

  20. Jaffe TA, Raiff D, Ho LM, Kim CY. Management of anticoagulant and antiplatelet medications in adults undergoing percutaneous interventions. Am J Roentgenol. 2015;205(2):421–8. https://doi.org/10.2214/AJR.14.13342.

    Article  Google Scholar 

  21. •• Narouze S, Benzon HT, Provenzano D, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications (second edition): Guidelines from the American Society of Regional Anesthesia and Pain Medicine. Eur Soc Region Anaesth Pain Ther. 2018. https://doi.org/10.1097/AAP.0000000000000700. This reference is the updated guidelines from multiple societies concerned with regional anesthesia including the American Society of Regional Anesthesia and Pain Medicine, for perioperative management of antiplatelets and anticoagulants for interventional pain and spine procedures with recommendations that are either evidence-based or pharmacology driven, and consider the bleeding risk of procedures in addition to other factors.

  22. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40(2):124–32. https://doi.org/10.1177/00912700022008766.

    Article  CAS  PubMed  Google Scholar 

  23. Barker JM. The thienopyridines. Adv Heterocycl Chem. 1977;21:65–118. https://doi.org/10.1016/S0065-2725(08)60730-8.

    Article  CAS  Google Scholar 

  24. Bhindi R, Testa L, Biondi Zoccai GGL, et al. Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents. Adv Hematol. 2010. https://doi.org/10.1155/2010/595934.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Steimle AE, Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease [5] (multiple letters). N Engl J Med. 2004;350(20):2101–2. https://doi.org/10.1056/NEJM200405133502020.

    Article  CAS  PubMed  Google Scholar 

  26. Norgard NB, Abu-Fadel M. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag. 2009;5:873–82. https://doi.org/10.2147/vhrm.s5699.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Testa L, Zoccai GGLB, Valgimigli M, et al. Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents. Adv Hematol. 2010. https://doi.org/10.1155/2010/595934.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Benzon HT, Mccarthy RJ, Benzon HA, et al. Determination of residual antiplatelet activity of clopidogrel before neuraxial injections. Br J Anaesth. 2011;107:966–71. https://doi.org/10.1093/bja/aer298.

    Article  CAS  PubMed  Google Scholar 

  29. Marczewski MM, Postula M, Kosior D. Novel antiplatelet agents in the prevention of cardiovascular complications - focus on ticagrelor. Vasc Health Risk Manag. 2010;6(1):419–29. https://doi.org/10.2147/vhrm.s7054.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50(1):27–35. https://doi.org/10.1177/0091270009344986.

    Article  CAS  PubMed  Google Scholar 

  31. Baber U, Dangas G, Cohen DJ, et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study. Am Heart J. 2016;182:125–34. https://doi.org/10.1016/j.ahj.2016.09.006.

    Article  CAS  PubMed  Google Scholar 

  32. Oestreich JH, Steinhubl SR. Cangrelor in percutaneous coronary intervention. Expert Rev Clin Pharmacol. 2009;2(2):137–45. https://doi.org/10.1586/17512433.2.2.137.

    Article  CAS  PubMed  Google Scholar 

  33. Lemon SJ, Flynn JD, Dunn SP. Perioperative management of antiplatelet therapy in patients with cardiovascular disease. Orthopedics. 2008;31(12):1210. https://doi.org/10.3928/01477447-20081201-10.

    Article  Google Scholar 

  34. Schneider DJ, Aggarwal A. Development of glycoprotein IIb–IIIa antagonists: translation of pharmacodynamic effects into clinical benefit. Expert Rev Cardiovasc Ther. 2004;2(6):903–13. https://doi.org/10.1586/14779072.2.6.903.

    Article  CAS  PubMed  Google Scholar 

  35. Subban V, Sarat CK. Glycoprotein IIb–IIIa inhibitors - do we still need them? Indian Heart J. 2013;65(3):260–3. https://doi.org/10.1016/j.ihj.2013.04.032.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Lippi G, Montagnana M, Danese E, Favaloro EJ, Franchini M. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy. Biomark Med. 2011;5(1):63–70. https://doi.org/10.2217/bmm.10.119.

    Article  CAS  PubMed  Google Scholar 

  37. De Luca G. Glycoprotein IIb–IIIa inhibitors. Cardiovasc Ther. 2012;30(5):242–54. https://doi.org/10.1111/j.1755-5922.2011.00293.x.

    Article  CAS  Google Scholar 

  38. Lee LY, DeBois W, Krieger KH, et al. The effects of platelet inhibitors on blood use in cardiac surgery. Perfusion. 2002;17(1):33–7. https://doi.org/10.1191/0267659102pf532oa.

    Article  PubMed  Google Scholar 

  39. Wessler JD, Giugliano RP. Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials. Eur Heart J. 2015. https://doi.org/10.1093/ehjcvp/pvu008.

    Article  Google Scholar 

  40. Karathanos A, Lin Y, Dannenberg L, et al. Routine glycoprotein IIb/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a meta-analysis. Can J Cardiol. 2019. https://doi.org/10.1016/j.cjca.2019.05.003.

    Article  PubMed  Google Scholar 

  41. Schrör K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002;4(SUPPL. 2):14–9. https://doi.org/10.1046/j.1463-1326.2002.0040s2s14.x.

    Article  Google Scholar 

  42. Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother. 2000;34(11):1283–90. https://doi.org/10.1345/aph.10079.

    Article  CAS  PubMed  Google Scholar 

  43. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg. 2011;112(2):292–318. https://doi.org/10.1213/ANE.0b013e318203f38d.

    Article  CAS  PubMed  Google Scholar 

  44. Abdulsattar Y, Ternas T, Garcia D. Vorapaxar: targeting a novel antiplatelet pathway. P T. 2011;36(9):564–8.

    PubMed  PubMed Central  Google Scholar 

  45. Tantry US, Liu F, Chen G, Gurbel PA. Vorapaxar in the secondary prevention of atherothrombosis. Expert Rev Cardiovasc Ther. 2015;13(12):1293–305. https://doi.org/10.1586/14779072.2015.1109447.

    Article  CAS  PubMed  Google Scholar 

  46. • Acosta RD, Abraham NS, Chandrasekhara V, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016;83(1):3–16. https://doi.org/10.1016/j.gie.2015.09.035. This reference is the American Society of Gastroenterology guidelines for management of anticoagulants and antiplatelets prior to upper GI endoscopy.

  47. Kei A, Elisaf M. Vorapaxar in secondary prevention: where we stand. Curr Med Res Opin. 2017;33(11):2077–9. https://doi.org/10.1080/03007995.2017.1341405.

    Article  PubMed  Google Scholar 

  48. Hirsh J, O’Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation. 2007;116(5):552–60. https://doi.org/10.1161/CIRCULATIONAHA.106.685974.

    Article  CAS  PubMed  Google Scholar 

  49. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001;21(7):1094–6. https://doi.org/10.1161/hq0701.093686.

    Article  CAS  PubMed  Google Scholar 

  50. Oates JA, Alastair JJ. Drug therapy: heparin. N Engl J Med. 1991;324(22):1565.

    Article  Google Scholar 

  51. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133:815S-843S. https://doi.org/10.1378/chest.08-0686.

    Article  CAS  PubMed  Google Scholar 

  52. Eisenberg PR. Mechanism of action of heparin and anticoagulant therapy: implications for the prevention of arterial thrombosis and the treatment of mural thrombosis. Coronary Artery Disease, vol. 1, no. 2. 1990; https://oce-ovid-com.proxy.lib.wayne.edu/article/00019501-199003000-00003/HTML. Accessed July 22, 2020.

  53. Planès A. Review of bemiparin sodium - a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin Pharmacother. 2003;4(9):1551–61. https://doi.org/10.1517/14656566.4.9.1551.

    Article  PubMed  Google Scholar 

  54. Lin PJ. Reviewing the reality: why we need to change. Eur Heart J. 2005;7:15–20. https://doi.org/10.1093/eurheartj/sui031.

    Article  CAS  Google Scholar 

  55. Geerts WH, Pineo GF. Thromboembolism the seventh ACCP conference on antithrombotic and thrombolytic. Chest. 2004;126(3):338S-400S. https://doi.org/10.1378/chest.126.3.

    Article  CAS  PubMed  Google Scholar 

  56. Md Arif K, Rahman MA. A review of warfarin dosing and monitoring. Faridpur Med Coll J. 2018;13(1):40–3. https://doi.org/10.3329/fmcj.v13i1.38018.

    Article  Google Scholar 

  57. Gulati G, Hevelow M, George M, Behling E, Siegel J. International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy. Arch Pathol Lab Med. 2011;135(4):490–4. https://doi.org/10.1043/2009-0474-OA.1.

    Article  PubMed  Google Scholar 

  58. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41(9):1633–52. https://doi.org/10.1016/S0735-1097(03)00416-9.

    Article  CAS  PubMed  Google Scholar 

  59. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995;122(1):40–2. https://doi.org/10.7326/0003-4819-122-1-199501010-00006.

    Article  CAS  PubMed  Google Scholar 

  60. Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Hematol Am Soc Hematol Educ Progr. 2012;2012(24):529–35. https://doi.org/10.1182/asheducation.v2012.1.529.3799663.

    Article  Google Scholar 

  61. Bertesi M. A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery. Clin Lab Haematol. 2003;25:127–30.

    Article  PubMed  Google Scholar 

  62. Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther M. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombol. 2008;25(1):96–96. https://doi.org/10.1007/s11239-007-0138-1.

    Article  Google Scholar 

  63. Jaffer AK, Ahmed M, Brotman DJ, et al. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombol. 2005;20(1):11–6. https://doi.org/10.1007/s11239-005-3120-9.

    Article  Google Scholar 

  64. Bergqvist D. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery. Vasc Health Risk Manag. 2006;2(4):365–70. https://doi.org/10.2147/vhrm.2006.2.4.365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–77. https://doi.org/10.2147/TCRM.S84210.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Kamath SD, Mcmahon BJ. Update on anticoagulation: what the interventional radiologist needs to know. Semin Intervent Radiol. 2016;33(2):122–31. https://doi.org/10.1055/s-0036-1582124.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Dubois V, Dincq AS, Douxfils J, et al. Perioperative management of patients on direct oral anticoagulants. Thromb J. 2017;15(1):1–18. https://doi.org/10.1186/s12959-017-0137-1.

    Article  CAS  Google Scholar 

  68. Huisman MV, Klok FA. Pharmacological properties of betrixaban. Eur Hear J. 2018;20(Suppl E):E12–5. https://doi.org/10.1093/eurheartj/suy016.

    Article  CAS  Google Scholar 

  69. Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375(6):534–44. https://doi.org/10.1056/nejmoa1601747.

    Article  CAS  PubMed  Google Scholar 

  70. Yong JW, Yang LX, Ohene BE, Zhou YJ, Wang ZJ. Periprocedural heparin bridging in patients receiving oral anticoagulation: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017. https://doi.org/10.1186/s12872-017-0719-7.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1–22. https://doi.org/10.2165/0003088-200948010-00001.

    Article  CAS  PubMed  Google Scholar 

  72. Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res. 2011;127(SUPPL. 2):S5–12. https://doi.org/10.1016/S0049-3848(10)70147-X.

    Article  CAS  PubMed  Google Scholar 

  73. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72(4):581–92. https://doi.org/10.1111/j.1365-2125.2011.03916.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Alatri A, Armstrong AE, Greinacher A, et al. Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. Thromb Res. 2012;129(4):426–33. https://doi.org/10.1016/j.thromres.2011.11.041.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Radiology, Detroit Medical Center, Detroit, MI, USA

    Mohamed S. Abbas, Ali N. Harb, Roger K. Kakos, Kristian Loveridge & Hani H. Abujudeh

  2. Faculty of Medicine, Ain-Shams University, Cairo, Egypt

    Mahmoud S. Abbas

Authors
  1. Mohamed S. Abbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahmoud S. Abbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali N. Harb
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roger K. Kakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kristian Loveridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hani H. Abujudeh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed S. Abbas.

Ethics declarations

Conflict of interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Quality and Safety.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abbas, M.S., Abbas, M.S., Harb, A.N. et al. Periprocedural Anticoagulation and Antiplatelet Medications Management for Interventional Radiology Procedures. Curr Radiol Rep 9, 5 (2021). https://doi.org/10.1007/s40134-021-00380-8

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40134-021-00380-8

Keywords

Search

Navigation